Live from the Nazac Market site in the heart of New York City's Times Square.

This is fast money. Here's what's on tap tonight. A strong start.

December picking up right where November left off rates keep falling. St stocks keep rising in from tech to

regionals to the consumer it's a sea of green should investors keep riding the

momentum through year end. We'll debate that. Plus big fat fail. Pfizer

pulling the plug on its twice a day weight loss pill is too many patients

said no moss to the drug because of the side effects. Is Pfizer in danger of being left out of the

obesity boom? Plus it's Friday and that means it is time for a little

options action. Professor Cohen the Chartmaster together again. They're ready to

wrap about the regional banks coming up. I'm Melissa Lee coming to you live

from Studio B at the Nasazac on the desk tonight.

C. Graso, Fano Anison, Carter Worth, and Mike Co.

We'll get to the market strong start to December in a minute, but we begin with Pfizer

and its super-ized losses today.

The sock falling more than 5% to its lowest level since March 2020.

After the drug giant announced it is pulling the plug on its twice daily weight loss pill,

Pfizer saying patients struggle to deal with

the side effects from taking this medicine.

For the year, Pfizer is now down over 43 percent, badly lagging its obesity drug rivals.

Eli Lilly nearly 60% higher on the year

while Novo Nordisk is up 48%. Here now to take us inside today's setback

the NBC's Angelica pebels. Hey Angelica. Hey Melissa, yeah, so Pfizer's ambitions in the obesity space falling behind today after the drug

...